

Supplementary

Table S1 Univariate and multivariate cox regression analyses of prognostic factors for CSS of elderly-onset PanNEC without treatment

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age (years)				
<75	1.00 (reference)		1.00 (reference)	
≥75	2.09 (1.54-2.85)	<0.001	2.25 (1.63-3.10)	<0.001
Sex				
Female	1.00 (reference)			
Male	0.97 (0.72-1.30)	0.83		
Race				
White	1.00 (reference)			
Black	1.06 (0.69-1.64)	0.79		
Others	1.05 (0.64-1.71)	0.86		
Marital status				
Married	1.00 (reference)			
Others	0.84 (0.61-1.16)	0.29		
Primary site				
Body and tail	1.00 (reference)			
Head	1.26 (0.88-1.80)	0.21		
Others	1.32 (0.89-1.97)	0.17		
Tumor size (mm)				
≤20	1.00 (reference)			
21-40	0.74 (0.39-1.38)	0.34		
>40	0.83 (0.45-1.51)	0.54		
Unknown	0.89 (0.45-1.75)	0.73		
TNM stage				
I	1.00 (reference)		1.00 (reference)	
II/III	3.51 (1.04-11.79)	0.042	2.88 (0.84-9.87)	0.09
IV	5.97 (1.89-18.87)	0.002	4.12 (1.27-13.40)	0.02
Liver metastasis				
No	1.00 (reference)		1.00 (reference)	
Yes	2.04 (1.46-2.84)	<0.001	1.76 (1.17-2.66)	0.007
Lymph nodes metastasis				
No	1.00 (reference)			
Yes	0.94 (0.68-1.29)	0.70		
Unknown	0.93 (0.48-1.77)	0.82		

Table S1 (*continued*)

Table S1 (continued)

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Bone metastasis				
No	1.00 (reference)			
Yes	1.29 (0.82-2.01)	0.27		
Unknown	2.34 (0.95-5.72)	0.06		
Brain metastasis				
No	1.00 (reference)			
Yes	1.34 (0.55-3.28)	0.52		
Unknown	2.18 (0.96-4.94)	0.06		
Lung metastasis				
No	1.00 (reference)		1.00 (reference)	
Yes	0.99 (0.66-1.50)	0.98	0.80 (0.53-1.22)	0.31
Unknown	3.70 (1.35-10.12)	0.01	2.34 (0.85-6.44)	0.10

CSS, cancer-specific survival; PanNEC, pancreatic neuroendocrine carcinoma; HR, hazard ratio; CI, confidence interval; TNM, tumor, nodes, and metastasis.




Figure S1 Cancer-specific survival curve of elderly-onset pancreatic neuroendocrine carcinoma in training dataset by TNM stage. TNM, tumor, nodes, and metastasis.




Figure S2 Nomogram of the cancer-specific survival for elderly-onset pancreatic neuroendocrine carcinoma without treatment. TNM, tumor, nodes, and metastasis.




Figure S3 Calibration of the nomogram without treatment for half year (A in training dataset; D in validation dataset), one year (B in training dataset; E in validation dataset) and two years (C in training dataset; F in validation dataset) CSS of elderly-onset pancreatic neuroendocrine carcinoma. CSS, cancer-specific survival.




Figure S4 ROC of the nomogram without treatment for half year, one year and two years cancer-specific survival of elderly-onset pancreatic neuroendocrine carcinoma in training dataset (A) and validation dataset (B). AUC, area under the ROC curve; ROC, receiver operating characteristic.




Figure S5 DCA of the nomogram without treatment for half year, one year and two years cancer-specific survival of elderly-onset pancreatic neuroendocrine carcinoma in training dataset (A) and validation dataset (B). DCA: decision curve analysis.